Expression and clinical significance of FoxM1 and ADAM17 in breast cancer

Yan ZHANG,Weichao QIAO,Ying SUN,Xuepeng ZHANG
2016-01-01
Abstract:Objective To explore expression and clinical significance of FoxM1 and ADAM17 in human breast cancer. Methods Expression of FoxM1 and ADAM17 were detected in 62 cases of invasive breast cancer (breast cancer group), 32 cases of breast fibroadenoma (breast fibroadenoma group) and 31 cases of normal breast tissue (control group) by im-munohistochemical staining. All patients were treated in Affiliated Hospital, North China University of Science and Technology from June 2014 to December 2015. The correlation between immunohistochemical staining results and clin-ical pathological features of breast cancer group were analyzed. Results Staining index of FoxM1 and ADAM17 in the control group, breast fibroadenoma group and breast cancer group were 0.49±0.11, 2.13±0.25, 9.58±0.95 and 0.56±0.17, 1.87±0.22, 9.40±1.17, respectively. Expression of FoxM1 and ADAM17 in breast cancer group were significant higher than that in breast fibroadenoma group (P < 0.05). Compared with control group, expression of FoxM1 and ADAM17 in breast fibroadenoma group were much higher (P<0.05). The expression of FoxM1 and ADAM17 was not associated with age and tumor size in patients with breast cancer (P>0.05) , but it was associated with the metastasis of axillary lymph nodes (P< 0.05). Correlation analysis showed that the expression of FoxM1 and ADAM17 in breast cancer was positively correlated (r=0.68, P<0.05). Conclusion There is high level of FoxM1 and ADAM17 in inva-sive carcinoma, and a positive correlation between them. Positive expression of FoxM1 and ADAM17 is positive associ-ation with axillary lymph node metastasis, but not with age and tumor size in patients with invasive carcinoma of the breast.
What problem does this paper attempt to address?